Studies how Trikafta affects breathlessness and exercise in cystic fibrosis
Follows adults with cystic fibrosis taking Trikafta to observe breathing during exercise.
Plain-language title generated from the registry record
Registry title: Trikafta Exercise Study in Cystic Fibrosis
Key facts
- Where
- Vancouver, CanadaSee the site
Where in Canada
- UBC Centre for Heart Lung Innovation, St. Paul's HospitalVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of British Columbia
- Trial code
- NCT05279040
- Record updated
- 18 May 2026
- Original description
Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.Read full original descriptionShow less
Long-term Effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Exertional Symptoms, Exercise Performance, Ventilatory Responses, and Body Composition in Adults With Cystic Fibrosis
Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.
Inclusion: Confirmed diagnosis of CF and at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; Plan to initiate Trikafta by the treating physician within 30 days of the enrolment visit; Aged 19 years or older; Stable clinical status based on clinical judgment of the treating physician; Forced Expiratory Volume in 1 second (FEV1.0) < 90% predicted; Body mass index greater than 16 or less than 30 kg/m\^2; Currently non-smoking or a past smoking history of less than 20 pack-years; Able to read and understand English; Fully vaccinated (at least 2 doses) for Covid-19.
Exclusion: A disease other than CF that could importantly contribute to dyspnea or exercise limitation; Chronic airway infection with Mycobacterium abscessus, Burkholderia cepacia complex, or other organisms with infection control implications based on the treating physicians; History of organ transplantation; Contraindications to clinical exercise testing; Use of supplemental oxygen or desaturation less than 85% with exercise; Diagnosis of pneumothorax in the past 4 weeks.